생물학적 제제 위탁생산 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 적응증별, 지역별, 부문별 예측(2025-2030년)

Biologics Contract Manufacturing Market Size, Share & Trends Analysis Report By Product (MABs, Recombinant Protein), By Indication (Oncology, CVDs), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,374,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,782,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,597,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

생물학적 제제 위탁생산 시장 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 생물학적 제제 위탁생산 시장 규모는 2025-2030년까지 연평균 10.3%의 CAGR을 기록하며 2030년에는 575억 9,000만 달러에 달할 것으로 예측됩니다. 세계 시장은 COVID-19 팬데믹 기간 동안 효율적으로 성장했습니다. 이는 COVID-19 백신 개발을 위한 연구개발 활동이 활발해졌기 때문입니다. 또한 감염 확산을 억제하기 위한 제조 시설의 확장도 있었습니다. 예를 들어, 2021년 11월 론자는 향후 프로젝트를 지원하기 위해 스위스의 미생물 개발 연구소를 확장하기로 결정했다고 발표했습니다.

팬데믹 이후에는 여러 가지 근본적인 변화가 일어날 것으로 예상됩니다. 코로나 바이러스 백신 및 치료제 개발을 위한 생산 및 제조 노력이 증가하고, 모든 사업부문에 걸쳐 디지털 기능이 강화될 것으로 예상됩니다. 이러한 노력은 제약사와의 전략적 파트너십을 구축하는 데 있어 공동 계획에 도움이 될 것으로 보입니다. 예를 들어, 2022년 1월 론자는 생물 특이적 항체를 발견하고 설계하는 데 사용되는 기술을 발표했으며, 이 기술은 bYlok(TM)이라고 불립니다. 의약품 및 생물학적 제제 제조 아웃소싱은 전 세계적으로 빠르게 증가하고 있습니다.

제약회사 및 바이오테크놀러지 기업들은 의약품 및 생물학적 제제 제조와 관련된 운영비용을 절감하는 동시에 핵심 프로젝트에 집중하고 있습니다. 위탁생산기관(CMO)은 제조의 전 과정을 전문적으로 수행하고 경험이 풍부합니다. 생물학적 제제의 자체 제조는 복잡한 과정이고 많은 자원이 필요하기 때문에 어려운데, CMO는 신약 개발 프로세스 개선에 집중함으로써 수요와 공급의 격차를 해소하고, 그 결과 생물학적 제제를 환자에게 더 빨리 제공할 수 있습니다. 따라서 아웃소싱은 빠르게 증가하고 있습니다.

생물학적 제제 위탁생산 시장 보고서 하이라이트

• 제품별로는 MAB가 암, 감염, 천식, 자가면역질환 등 다양한 질환의 치료에 사용되면서 MAB 부문이 2024년 가장 큰 매출 점유율을 차지했습니다.
• 적응증별로는 암 분야가 2024년 가장 큰 매출 점유율로 시장을 장악했습니다. 이 부문의 높은 점유율의 주요 요인은 암 환자 수의 증가에 기인합니다.
• 북미는 의약품 및 생물학적 제제 제조의 아웃소싱 서비스가 증가하고 있으며, 연구개발비가 높아 2024년 세계 시장을 석권했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 생물학적 제제 위탁생산 시장 변수, 동향, 범위

• 시장 계통 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 산업 분석 - Porter's Five Forces 분석
  • PESTLE 분석

제4장 생물학적 제제 위탁생산 시장 : 제품 비즈니스 분석

• 제품 시장 점유율, 2024년과 2030년
• 제품 부문 대시보드
• 시장 규모와 예측과 동향 분석, 제품별, 2018-2030년
• 단클론항체(mAbs)
• 재조합 단백질
• 백신
• 안티센스, RNAi, 분자 요법
• 기타

제5장 생물학적 제제 위탁생산 시장 : 적응증 비즈니스 분석

• 적응증 시장 점유율, 2024년과 2030년
• 적응증 부문 대시보드
• 시장 규모와 예측과 동향 분석, 적응증별, 2018-2030년
• 종양학
• 자가면역질환
• 감염증
• 심혈관질환
• 대사성 질환
• 신경학
• 기타

제6장 생물학적 제제 위탁생산 시장 : 제품과 적응증에 의한 지역별, 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년과 2030년
• 지역별 시장 대시보드
• 시장 규모와 예측 동향 분석, 2018-2030년
• 북미
  • 국가별, 2018-2030년
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 국가별, 2018-2030년
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 태국
  • 한국
• 라틴아메리카
  • 국가별, 2018-2030년
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 국가별, 2018-2030년
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제7장 경쟁 구도

• 참여자 개요
• 기업의 시장 포지션 분석
• 기업 분류
• 전략 매핑
• 기업 개요/상장 기업
  • Wuxi Biologics.
  • FUJIFILM Diosynth BIoTechnologies.
  • Boehringer Ingelheim International GmbH
  • Lonza
  • Samsung Biologics
  • AbbVie Inc.
  • Catalent
  • Bioreliance(Merck KGaA)
  • Thermo Fisher Scientific Inc.
  • Eurofins Scientific

ksm

영문 목차

영문목차

Biologics Contract Manufacturing Market Growth & Trends:

The global biologics contract manufacturing market size is expected to reach USD 57.59 billion by 2030, registering a CAGR of 10.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. The global market was growing efficiently during the COVID-19 pandemic. This is due to a rise in R&D activities for the development of COVID-19 vaccines. In addition, there has been an expansion in manufacturing facilities to control the spread of the disease. For instance, in November 2021, Lonza announced that it has decided to expand its microbial development laboratories in Switzerland to support the company's upcoming projects.

It is believed that post-pandemic there will be numerous fundamental changes. There will be an increase in the production and manufacturing efforts for the development of vaccines and therapeutics against the coronavirus and a rise in digital capabilities across all their operating units. These initiatives will help them in joint planning with pharma clients in building more strategic partnerships. For instance, in January 2022, Lonza launched a technology that will be used for the discovery and design of antibodies that are biospecific and this technology will be called bYlok(TM). The outsourcing of drugs or biologics manufacturing is rapidly increasing around the world.

Pharmaceutical and biotechnology companies concentrate on their core projects while reducing the operational costs associated with manufacturing drugs or biologics. Contract Manufacturing Organizations (CMOs) are specialized and experienced in conducting the entire process of manufacturing. In-house manufacturing of biologics is difficult as it is a complex process and involves many resources. CMOs link the demand and supply gap by focusing on improving the drug discovery process resulting in faster availability of biologics for patients. Hence, due to these factors, outsourcing activities are rapidly increasing.

Biologics Contract Manufacturing Market Report Highlights:

• Based on products, the MABs segment accounted for the largest revenue share in 2024 as MABs are used in the treatment of a wide range of diseases, such as cancer, infectious diseases, asthma, and auto-immune diseases
• Based on indications, the oncology segment dominated the market in 2024 with the largest revenue share. The main factor responsible for the high segment share is the increased number of cancer cases
• North America dominated the global market in 2024 due to the increased outsourcing services for manufacturing drugs & biologics and high R&D expenditure in the region

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Indication
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Biologics Contract Manufacturing Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Biologics Contract Manufacturing Market: Product Business Analysis

• 4.1. Product Market Share, 2024 & 2030
• 4.2. Product Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Monoclonal Antibodies (mAbs)
  • 4.4.1. Monoclonal Antibodies (mAbs) Market, 2018 - 2030 (USD Million)
• 4.5. Recombinant Proteins
  • 4.5.1. Recombinant Proteins Market, 2018 - 2030 (USD Million)
• 4.6. Vaccines
  • 4.6.1. Vaccines Market, 2018 - 2030 (USD Million)
• 4.7. Antisense, RNAi, & Molecular Therapy
  • 4.7.1. Antisense, RNAi, & Molecular Therapy Market, 2018 - 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Biologics contract manufacturing Market: Indication Business Analysis

• 5.1. Indication Market Share, 2024 & 2030
• 5.2. Indication Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
• 5.4. Oncology
  • 5.4.1. Oncology Market, 2018 - 2030 (USD Million)
• 5.5. Autoimmune Diseases
  • 5.5.1. Autoimmune Diseases Market, 2018 - 2030 (USD Million)
• 5.6. Infectious Diseases
  • 5.6.1. Infectious Diseases Market, 2018 - 2030 (USD Million)
• 5.7. Cardiovascular Diseases
  • 5.7.1. Cardiovascular Diseases Market, 2018 - 2030 (USD Million)
• 5.8. Metabolic Diseases
  • 5.8.1. Metabolic Diseases Market, 2018 - 2030 (USD Million)
• 5.9. Neurology
  • 5.9.1. Neurology Market, 2018 - 2030 (USD Million)
• 5.10. Others
  • 5.10.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Biologics Contract Manufacturing Market: Regional Estimates & Trend Analysis by Product and Indication

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 6.4. North America
  • 6.4.1. North America Biologics Contract Manufacturing Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Regulatory Framework
    • 6.4.2.3. Competitive Insights
    • 6.4.2.4. U.S. Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Regulatory Framework
    • 6.4.3.3. Competitive Insights
    • 6.4.3.4. Canada Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Regulatory Framework
    • 6.4.4.3. Competitive Insights
    • 6.4.4.4. Mexico Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Biologics Contract Manufacturing Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Regulatory Framework
    • 6.5.2.3. Competitive Insights
    • 6.5.2.4. UK Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Regulatory Framework
    • 6.5.3.3. Competitive Insights
    • 6.5.3.4. Germany Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Regulatory Framework
    • 6.5.4.3. Competitive Insights
    • 6.5.4.4. France Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Regulatory Framework
    • 6.5.5.3. Competitive Insights
    • 6.5.5.4. Italy Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Regulatory Framework
    • 6.5.6.3. Competitive Insights
    • 6.5.6.4. Spain Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. Denmark
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Regulatory Framework
    • 6.5.7.3. Competitive Insights
    • 6.5.7.4. Denmark Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Sweden
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Regulatory Framework
    • 6.5.8.3. Competitive Insights
    • 6.5.8.4. Sweden Biologics Contract Manufacturing Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.5.9. Norway
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Regulatory Framework
    • 6.5.9.3. Competitive Insights
    • 6.5.9.4. Norway Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Regulatory Framework
    • 6.6.2.3. Competitive Insights
    • 6.6.2.4. Japan Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Regulatory Framework
    • 6.6.3.3. Competitive Insights
    • 6.6.3.4. China Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Regulatory Framework
    • 6.6.4.3. Competitive Insights
    • 6.6.4.4. India Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. Australia
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Regulatory Framework
    • 6.6.5.3. Competitive Insights
    • 6.6.5.4. Australia Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. Thailand
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Regulatory Framework
    • 6.6.6.3. Competitive Insights
    • 6.6.6.4. Thailand Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. South Korea
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Regulatory Framework
    • 6.6.7.3. Competitive Insights
    • 6.6.7.4. South Korea Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Biologics Contract Manufacturing Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Regulatory Framework
    • 6.7.2.3. Competitive Insights
    • 6.7.2.4. Brazil Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Regulatory Framework
    • 6.7.3.3. Competitive Insights
    • 6.7.3.4. Argentina Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.8. MEA
  • 6.8.1. MEA Biologics Contract Manufacturing Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Regulatory Framework
    • 6.8.2.3. Competitive Insights
    • 6.8.2.4. South Africa Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Regulatory Framework
    • 6.8.3.3. Competitive Insights
    • 6.8.3.4. Saudi Arabia Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Regulatory Framework
    • 6.8.4.3. Competitive Insights
    • 6.8.4.4. UAE Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Regulatory Framework
    • 6.8.5.3. Competitive Insights
    • 6.8.5.4. Kuwait Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. Wuxi Biologics.
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. FUJIFILM Diosynth Biotechnologies.
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Boehringer Ingelheim International GmbH
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Lonza
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Samsung Biologics
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. AbbVie Inc.
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Catalent
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. Bioreliance (Merck KGaA)
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Thermo Fisher Scientific Inc.
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. Eurofins Scientific
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives

관련자료